其他
社区获得性肺炎经验性抗感染治疗的临床微生物思维
参考文献（上下滑动，查看更多）
2.WangH, ChenM, XuY, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010[J]. Int J Antimicrob Agents, 2011, 38(5):376-383. DOI: 10.1016/j.ijantimicag.2011.06.015.3.WoodheadM. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns[J]. Eur Respir J Suppl, 2002, 36:20s-27s. DOI: 10.1183/09031936.02.00702002.4.赵春江, 张菲菲, 王占伟, 等. 2012年中国成人社区获得性呼吸道感染主要致病菌耐药性的多中心研究[J]. 中华结核和呼吸杂志, 2015, 1(38):18-22. DOI: 10.3760/cma.j.issn.1001-0939.2015.01.008.5.MoranGJ, KrishnadasanA, GorwitzRJ, et al.Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia[J]. Clin Infect Dis, 2012, 54(8):1126-1133. DOI: 10.1093/cid/cis022.6.LiuC, BayerA, CosgroveSE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary[J]. Clin Infect Dis, 2011, 52(3):285-292. DOI: 10.1093/cid/cir034.7.ZhaoC, LiuY, ZhaoM, et al. Characterization of community acquired Staphylococcus aureus associated with skin and soft tissue infection in Beijing: high prevalence of PVL+ST398[J]. PLoS One, 2012, 7(6):e38577. DOI: 10.1371/journal.pone.0038577.8.JungWJ, KangYA, ParkMS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia[J]. BMC Infect Dis, 2013, 13:370. DOI: 10.1186/1471-2334-13-370.9.KangCI, SongJH, OhWS, et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli[J]. Eur J Clin Microbiol Infect Dis, 2008, 27(8):657-661. DOI: 10.1007/s10096-008-0485-7.10.SongJH, KoKS, LeeMY, et al. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries[J]. Diagn Microbiol Infect Dis, 2006, 56(4):445-450. DOI: 10.1016/j.diagmicrobio.2006.07.010.11.Pop-VicasAE, D′AgataEM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital[J]. Clin Infect Dis, 2005, 40(12):1792-1798. DOI: 10.1086/430314.12.MandellLA, BartlettJG, DowellSF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults[J]. Clin Infect Dis, 2003, 37(11):1405-1433. DOI: 10.1086/380488.13.NieW, LiB, XiuQ. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2014, 69(6):1441-1446. DOI: 10.1093/jac/dku033.14.AsadiL, SliglWI, EurichDT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis[J]. Clin Infect Dis, 2012, 55(3):371-380. DOI: 10.1093/cid/cis414.15.MandellLA, WunderinkRG, AnzuetoA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2007, 44Suppl2 (Suppl 2):S27-72. DOI: 10.1086/511159.16.YuVL, GreenbergRN, ZadeikisN, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis[J]. Chest, 2004, 125(6):2135-2139. DOI: 10.1378/chest.125.6.2135.17.Blázquez GarridoRM, Espinosa ParraFJ, AlemanyFrancésL, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides[J]. Clin Infect Dis, 2005, 40(6):800-806. DOI: 10.1086/428049.18.FukudaY, YanagiharaK, HigashiyamaY, et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae[J]. Eur Respir J, 2006, 27(5):1020-1025. DOI: 10.1183/09031936.06.00116805.19.KobayashiH. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides[J]. Am J Med, 1995, 99(6A):26S-30S. DOI: 10.1016/S0002-9343(99)80282-4.20.TatedaK, ComteR, PechereJC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2001, 45(6):1930-1933. DOI: 10.1128/AAC.45.6.1930-1933.2001.21.CunhaBA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?[J] Chest, 2004, 125(5):1913-1919. DOI: 10.1378/chest.125.5.1913.